JNJ - Is Johnson & Johnson a Buy in April?
Johnson & Johnson (NYSE: JNJ) is the very definition of a value stock : five consecutive years of annual revenue growth, an above-average dividend that has been raised for 58 consecutive years in a row, and a diversified product portfolio capable of weathering various lawsuits, pandemics, and whatever else gets thrown its way.
Last week, it was reported that a batch of 15 million doses of the company's vaccine that was being made for Johnson & Johnson by Emergent BioSolutions (NYSE: EBS) had to be thrown out because a mistake had been made regarding one of the batch's ingredients. Emergent's stock dropped on the news; J&J stock didn't. Now, Johnson & Johnson has been directed by the U.S. government to take over vaccine operations at the facility.
That's how it goes when you are one of the world's biggest, baddest companies in healthcare, with a market cap of $429 billion.
For further details see:
Is Johnson & Johnson a Buy in April?